Brawn Biotech (BSE: BRAWN) had a P/E of 7.3× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 21% below their 52-week high. Its ROCE of 0.1% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales fell 11% a year over 3 years, though net profit is above operating profit, which points to a one-off gain. It is a small-cap company with a market cap of ₹6.32 Cr, ranked 152nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 9.9% over the past year.
- ₹22.10
- ₹22.10
- ₹21.05
- ₹22.10
- 195
Health check
- ReturnsBehind
+9.9% over a year, better than 2 of 7 peers.
- Price tagDistorted
A one-off gain inflates profit, so P/E isn’t comparable right now.
- GrowthShrinking
Sales −11.1% a year over 3 years.
- ProfitabilityWeak
ROCE 0.1% vs peer median 17.9%.
- Balance sheetStretched
Piotroski 5 of 9.
- Red flags3 to check
Quarterly profit down 34.6% on a year ago.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹6.32 Cr
- Small cap
- P/E
- 7.3
- Industry 28.7
- Price to book
- 1.46
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 24.4%
- Peers 14.7%
- ROCE
- 0.1%
- Peers 17.9%
- Debt to equity
- n/a
- Debt ₹0.00 Cr
- EPS (TTM)
- ₹2.89
- OPM (TTM)
- −2.6%
- Net margin 5.0%
- Sales growth
- +4.9%
- Latest quarter vs a year ago
- Profit growth
- −34.6%
- Latest quarter vs a year ago
- Price to sales
- 0.37
- EV/EBITDA −13.2
Strengths and risks
Strengths
- Return on equity of 24.4%.
Risks to check
- Quarterly profit down 34.6% on a year ago.
- Net profit is above operating profit, so a one-off gain is likely flattering earnings.
- Interest coverage of only −114.7×.
About Brawn Biotech
Brawn Biotech Limited trades in pharmaceutical products in India. It provides pharmaceutical formulations, including antibacterial, cardiovascular, antidiabetic, analgesic, gastrointestinal, antifungal, skin care, antipsychotic, antiasthmatic, antacid, antimalarial, and nutritional products. The company was formerly known as Brawn Pharmaceuticals Limited and changed its name to Brawn Biotech Limited in November 2010. The company was incorporated in 1985…
- Headquarters
- New Delhi
- Employees
- 6
- Sector
- Healthcare
- ISIN
- INE899B01015
- Website
- brawnbiotech.com
Price range
- Avg volume (3M)
- 483
- 1-year return
- plus 9.9%
- From 52-week high
- minus 21.0%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| BRAWNBrawn Biotech | 21.05 | minus 4.75% | 6 | 7.3 | 1.46 | 0.1% | 24.4% | −2.6% | −11.1% | – | 0.00% | plus 9.9% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 5.8 | 4.9 | 4.3 | 2 | 6.1 | |
| 5.6 | 4.9 | 4.3 | 2.5 | 6 | |
| 0.2 | 0 | −0 | −0.5 | 0 | |
| 3.0% | 0.3% | −0.3% | −25.5% | 0.8% | |
| 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0.2 | 0.1 | 0 | −0.4 | 0.2 | |
| – | – | – | 263.8% | – | |
| 0.2 | 0.1 | 0 | 0.6 | 0.2 | |
| 0.89 | 0.25 | 0.17 | 1.95 | 0.52 |
Profit & loss
- Sales CAGR 3Y
- −11.1%
- ROE
- 24.4%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 20.7 | 15.5 | 12 | 14.5 | |
| – | minus 24.9% | minus 22.9% | +21.4% | |
| 21 | 17 | 13.7 | 14.9 | |
| −0.3 | −1.5 | −1.8 | −0.3 | |
| −1.5% | −9.7% | −14.8% | −2.2% | |
| 0 | 0.1 | 0.1 | 0.4 | |
| 0 | 0.1 | 0 | 0 | |
| 0.1 | 0.1 | 0.1 | 0.1 | |
| – | −0 | 0 | – | |
| −0.4 | −1.5 | −1.8 | 0 | |
| −111.0% | 19.2% | 3.2% | −86994.3% | |
| −0.9 | −1.2 | −1.7 | 0.9 | |
| -2.89 | -4.16 | -5.68 | 3.26 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 3 | 3 | 3 | 3 | |
| 3.3 | 2.1 | 0.4 | 1.3 | |
| 8.2 | 9.5 | 17.1 | 16.5 | |
| 14.5 | 14.6 | 20.5 | 20.9 | |
| 0.4 | 0.3 | 0.5 | 0.4 | |
| 0.4 | 0.4 | 0.2 | 0.3 | |
| 13.7 | 13.9 | 19.8 | 20.2 | |
| 14.5 | 14.6 | 20.5 | 20.9 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 0.3 | −0 | 0 | 0.1 | |
| −0.1 | −0 | −0.2 | −0 | |
| −0 | −0 | −0 | −0 | |
| 0.2 | −0 | −0.2 | 0.1 | |
| −0.1 | −0 | −0.2 | −0 | |
| 0.2 | −0 | −0.2 | 0.1 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.